Key Takeaways:
UnitedHealth Group Inc. (NYSE: UNH) on Tuesday raised its full-year profit forecast after first-quarter results beat analyst estimates, as the nation’s largest health insurer showed progress in managing high medical costs that have pressured the industry.
“We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity,” UnitedHealth CEO Stephen Hemsley said in a statement.
The company reported first-quarter adjusted earnings of $7.23 per share on revenue of $111.72 billion. The results topped consensus estimates of $6.57 for earnings per share and $109.57 billion in revenue, according to LSEG data. A key metric, the medical care ratio, came in at 83.9 percent, an improvement from 84.8 percent a year earlier and better than the 85.5 percent analysts had forecast.
UnitedHealth now expects full-year 2026 adjusted earnings of more than $18.25 per share, an increase of at least 50 cents from its previous guidance of over $17.75. The improved outlook follows a recent boost to the sector after the Centers for Medicare and Medicaid Services finalized a 2.48 percent payment increase for 2027 Medicare Advantage plans, easing concerns after a near-flat rate was initially proposed.
The beat was driven by a strong performance in cost management and a recovery in the company's Optum health services division. The Optum segment reported $1.3 billion in adjusted operating earnings, a positive sign for the unit's turnaround. UnitedHealth has been focused on improving profitability by exiting less profitable Medicare Advantage markets and investing heavily in technology, earmarking at least $1.5 billion for AI initiatives this year to streamline operations.
Analysts reacted positively to the results and outlook. Ahead of the report, Morgan Stanley named the stock a “top pick,” setting a $375 price target. Separately, Jefferies maintained a ‘Buy’ rating and raised its target to $373, while Piper Sandler reiterated an ‘Overweight’ rating with a $399 target.
The stronger-than-expected quarter and guidance hike suggest UnitedHealth's turnaround strategy under its new leadership is gaining traction. Investors will watch for continued margin improvement at Optum and sustained cost control when the company reports second-quarter results to confirm the recovery is on a stable footing.
This article is for informational purposes only and does not constitute investment advice.
